The day Sri Lanka joined Buddhists worldwide in observing Vesak Full Moon Poya Day, a day of reverence to the Buddha, the tiny island nation received a "very special gift".
Ex-Peru head gets virus despite vaccination, criticized for lax personal protection globaltimes.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globaltimes.cn Daily Mail and Mail on Sunday newspapers.
The new recombinant COVID-19 vaccine, developed by the National Vaccine &Serum Institute, a R&D center of Sinopharm s bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday.
The vaccine is based on the structural features of the receptor binding domain (RBD) on the virus spike protein (S-protein). It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralizing antibodies.
The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.
New COVID Vaccine for Clinical Trials Approved by Colleen Fleiss on April 12, 2021 at 10:16 PM
China s Sinopharm COVID-19 vaccine has recently been approved for clinical trials.
The new recombinant Covid-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D centre of Sinopharm s bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday, Xinhua reported.
It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralising antibodies.
‘The COVID-19 vaccine is based on the structural features of the receptor binding domain (RBD) on the virus spike protein (S-protein).’